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bjectives We evaluated the association between guiding catheter size and complications of per-
utaneous coronary intervention (PCI).
ackground The association between guiding catheter size and complications of PCI in contempo-
ary practice remains controversial.
ethods Procedure and outcome variables from 103,070 consecutive patients that underwent PCI
ith 6-F (n  64,335), 7-F (n  32,676), and 8-F (n  6,059) guide catheters were compared.
esults Compared with 6-F guides, PCIs performed with 7- and 8-F guides were associated with
ncrementally more contrast agent use, and more post-PCI complications including contrast-induced
ephropathy, vascular access site complications, bleeding, transfusion, major adverse cardiac event,
nd death. After multivariate analysis, the use of larger guides were associated with a higher risk of
ontrast-induced nephropathy (7-F odds ratio [OR]: 1.18, p  0.0004; 8-F OR: 1.44, p  0.0001), vas-
ular complications (7-F OR: 1.19, p  0.0002, 8-F OR: 1.68, p  0.0001), decline in hemoglobin 3
/dl (7-F OR: 1.12, p  0.0001, 8-F OR: 1.72, p  0.0001), and post-procedure blood transfusion (7-F
R: 1.08, p  0.03; 8-F OR: 1.80, p  0.0001), whereas major adverse cardiac events (7-F OR: 1.06,
 0.13; 8-F OR: 1.37, p  0.0001) and in-hospital mortality (7-F OR: 1.11, p  0.13; 8-F OR: 1.34,
 0.03) were increased with 8-F but not 7-F guides.
onclusions Compared with 6-F guides, PCIs performed with 7- and 8-F guides were associated
ith more contrast medium use, renal complications, bleeding, vascular access site complications,
reater need for post-procedure transfusion, and 8-F guides with increased nephropathy requiring
ialysis, in-hospital major adverse cardiac events, and mortality. These data suggest that selection of
maller guide catheters may result in improved clinical outcome in patients undergoing contempo-
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637ercutaneous coronary intervention (PCI) procedural out-
omes and complications have been related to many patient
actors (1–6) and procedural (7,8), operator (9), and insti-
utional (10–12) variables. Over the last few years, changes
n technology have facilitated the performance of PCI with
maller guiding catheters. However, a number of operators
avor larger-sized guiding catheters based on perceived
etter support and ease of use, and to provide more options
o treat complex or bifurcation lesions and to use atheroa-
lative devices. Whether the size of the catheter used during
CI impacts procedural outcomes and complications is
nclear. We sought to evaluate the impact of guiding
atheter size on PCI associated complications in a multi-
enter, regional consortium of health care institutions that
erform contemporary PCI.
ethods
tudy design. The study sample had 103,070 consecutive
atients who underwent PCI with 6-, 7-, or 8-F guide
atheters, between January 2001 and December 2006 at 21
nstitutions. The consortium and data collection process
ave been described previously (13,14). The study was
pproved by the Institutional Review Board of the Univer-
ity of Michigan and the other local institutional review boards.
Clinical, procedural, and outcome data were collected
rospectively on a uniform data form at each participating
enter. Procedural variables, such as guiding catheter size,
nd contrast agent volume were collected in all cases.
atient variables such as age, sex, comorbidities, baseline
nd post-PCI hemoglobin (Hgb) and creatinine were re-
orded. Outcome measure definitions included were as
ollows. Nephropathy requiring dialysis was defined as a
ecrease in renal function requiring peritoneal dialysis or
emodialysis. Contrast-induced nephropathy (CIN) was
efined as an increase in serum creatinine 0.5 mg/dl over
aseline. In-hospital death was defined as death from either
cardiac or noncardiac cause. Vascular complications were
efined as any vascular complication, including pseudoan-
urysm, arteriovenous fistula, femoral neuropathy, retroper-
toneal hematoma, any complication requiring surgical re-
air, and hematoma requiring transfusion, prolonged
ospital stay, or causing a drop in Hgb 3.0 g/dl. Peripro-
edural myocardial infarction (MI) was defined as non–Q-
ave MI (any rise in creatinine phosphokinase-myocardial
and fraction above the normal at each individual institu-
ion within 24 h of PCI without new Q waves on an
lectrocardiogram) and Q-wave MI (development of new Q
aves that are 0.03 s in width and/or more than one-third of
he total QRS complex in contiguous leads and as evidenced
y subsequent creatine kinase-myocardial band rise to 3
imes the baseline value just before PCI). Major adverse
ardiovascular event (MACE) was defined as a composite of
troke, MI, death, post-PCI coronary artery bypass graft furgery (CABG) or post-PCI revascularization at the same
ite.
tatistical analysis. Baseline characteristics were expressed as
ean ( SD) and as percentages. Procedural and outcomes
ariables in patients undergoing PCI with 6-F guides were
ompared with those of patients undergoing PCI with 7- or
-F guides. The Student t test and analysis of variance were
sed for continuous variables, and the chi-square test was used
or categorical variables. Univariate and multivariate logistic
egression modeling was used to calculate unadjusted and
djusted odds of periprocedural events in association with 7- or
- versus 6-F guide catheter use.
To further adjust for the nonrandomized use of 8-F guides
nd for a possible selection bias in this cohort, a predictive
odel that adjusted for the propensity to receive an 8-F guide
ompared with a 6-F guide was also developed (15). The
robability, or a propensity score, of receiving an 8-F guide was
alculated using a nonparsimonious logistic regression model.
he variables included in the model were age, sex, prior history
f stroke, peripheral vascular disease, hypertension, diabetes,
ongestive heart failure, prior MI,
istory of renal failure with dialy-
is, prior gastrointestinal bleeding,
rior revascularization, chronic
bstructive airway disease, history
f smoking, serum creatinine and
gb, extent of coronary artery
isease, presence of thrombus or
alcification, pre-procedural med-
cation use, left ventricular ejec-
ion fraction before the interven-
ion, the year that the PCI was
erformed, and emergent PCI.
he propensity score was then
ncluded as an additional explanatory variable in the final models.
oreover, we used Greedy matching techniques to select patients
reated with 6-F guides as counterparts to patients treated with
-F guides by choosing the patient with the nearest propensity
core (16,17). In-hospital outcome was then compared within this
ropensity-matched cohort. Random effect models were fitted to
ontrol for variation by hospital. We estimated the univariate
tatistical significance of the effect of 8- versus 6-F guide use on
dverse outcomes using generalized estimating equations cluster
nalysis (18,19). Statistical analysis was performed with SAS (SAS
nstitute, Cary, North Carolina).
esults
aseline clinical characteristics are shown in Table 1. The
ean age of patients in this study was 64 years, 34% were
omen, and 33% were diabetic. Femoral arterial access was
sed in 98.9% of patients, brachial artery access in 0.5%, and
adial artery access in 0.6%. There were 6,059 PCIs per-
Abbreviations and
Acronyms
CABG  coronary artery
bypass graft surgery
CIN  contrast-induced
nephropathy
Hgb  hemoglobin
MACE  major adverse
cardiovascular event
MI  myocardial infarction
PCI  percutaneous
coronary interventionormed with 8-F guides, 32,676 with 7-F guides, and
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6384,335 with 6-F guides. Procedural characteristics are
hown in Table 2. More patients in the 7-F group had acute
r recent MI or underwent PCI of a restenotic lesion.
isible vessel calcification was more often identified in the
-F guide group. A larger percentage of patients in both the
- and 8-F groups had cardiogenic shock and multivessel
oronary artery disease and underwent multivessel PCI.
ascular closure devices were more often used in the 6-F
roup. Beginning in 2003, data related to 6-, 7-, or 8-F
uide catheter use for rotational atherectomy (1.43%,
.03%, and 4.23%, respectively, p  0.0001) and laser
therectomy (0.09%, 0.15%, and 0.25%, respectively, p 
.004) was collected. There were wide variations in the use
f 8-F guide catheters across various participating health
are institutions (Fig. 1).
When compared with PCIs performed with 6-F guides,
he use of 7- and 8-F guide catheters were associated with
he use of incrementally and significantly more contrast
edium, and use of a volume of contrast agent that
Table 1. Baseline Characteristics of the Cohort Based on Size of the Guidi
6-F
(n  64,335)
Demographic
Age, yrs 63.7 (12.2)
Female sex 35.2
Current smoking 25.9
Lean (BMI 25 kg/m2) 19.0
Obese (BMI 30 kg/m2) 44.3
Historical
Hypertension 77.7
Prior myocardial infarction 34.4
Diabetes mellitus 32.9
Congestive heart failure 12.7
Extracardiac vascular disease 23.0
Renal failure requiring dialysis 1.9
Signiﬁcant valve disease 4.3
Gastrointestinal bleeding 2.4
Prior PCI 38.9
Prior CABG 18.8
COPD 17.4
Laboratory
Baseline pre-Cr, mg/dl 1.18 (0.95)
Baseline Cr 1.5, mg/dl 11.6
Post-procedure Cr, mg/dl 1.26 (1.33)
Initial hemoglobin, g/dl 13.6 (1.9)
Pre-procedure WHO anemia 25.4
Nadir hemoglobin, g/dl 12.3 (2.03)
Ejection fraction 51.9 (11.4)
Ejection fraction 50% 29.2
Values are % (SD) or %.
BMI  body mass index; CABG  coronary artery bypass graft; COPD  chronic obstructive pu
WHOWorld Health Organization.xceeded the maximum allowable contrast medium dose aefined as contrast dose  [5 ml  kilogram (body
eight)/creatinine (mg/dl)] (20). Unadjusted outcomes in
atients undergoing PCI with 6-, 7-, and 8-F guides are
hown in Table 3. The larger guide catheters were associ-
ted with significantly more CIN and nephropathy requir-
ng dialysis. Post-procedure Hgb was more likely to fall by
3 g/dl in the 7- and 8-F guide patients. Similarly, there
ere significantly more blood transfusions in the 7- and 8-F
atheter groups. Vascular access site complications were
ore common in the 8-F group, regardless of whether
ascular closure devices were used. Compared with PCI
ith 6-F guides, the use of 7- or 8-F guides was also
ncrementally associated with unadjusted increased inci-
ence of myocardial infarction, stroke, MACE, and death.
After multivariate adjustment, when compared with 6-F
uide catheters, 7- and 8-F guides were associated with more
IN, post-PCI decrease in Hgb 3 g/dl, gastrointestinal
leeding, vascular complications, and post-procedure transfu-
ion (Table 4). In addition, 8-F guide catheters were also
theter
7-F 8-F
p Value(n  32,676) (n  6,059)
64.0 (12.3) 64.2 (12.3) 0.0002
32.9 32.4 0.0001
26.3 23.6 0.0001
19.0 18.3 0.43
44.1 45.7 0.07
79.9 76.8 0.0001
34.1 36.4 0.002
33.1 32.1 0.32
12.3 14.2 0.001
22.9 22.2 0.34
1.7 2.2 0.01
4.7 3.2 0.0001
2.0 2.1 0.0002
42.6 43.6 0.0001
20.3 20.9 0.0001
15.9 15.5 0.0001
1.19 (1.30) 1.22 (1.07) 0.03
12.2 13.5 0.0001
1.28 (1.22) 1.37 (1.52) 0.0001
13.7 (1.89) 13.5 (1.9) 0.0001
24.1 28.9 0.0001
12.2 (1.96) 11.7 (2.12) 0.0001
51.7 (12.0) 51.0 (12.3) 0.0001
31.0 31.6 0.0001
y disease; Cr  creatinine; PCI  percutaneous coronary intervention; SD  standard deviation;ng Ca
lmonarssociated with nephropathy requiring dialysis, post-PCI
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639mergency CABG, any post-PCI CABG, post-PCI MI,
eriprocedural in-hospital death, and MACE.
After adjusting for comorbidities and propensity (Fig. 2),
hen compared with 6-F catheters, the use of larger 8-F
uides was associated with a significantly higher risk of CIN
adjusted odds ratio [OR]: 1.35, 95% confidence interval [CI]:
.13 to 1.61, p  0.0009). In addition, 8-F catheters were
ssociated with significantly more vascular complications (ad-
usted OR: 1.73, 95% CI: 1.46 to 2.06, p  0.0001), more
requent post-procedure Hgb decrease of 3 g/dl (adjusted
Table 2. Procedural Characteristics of the Cohort Based on the Size of the
6-F
(n  64,335)
Emergency PCI 13.9
MI (7 days) 29.7
Acute MI (24 h) 16.0
Cardiogenic shock 1.9
Exceeding MACD* 7.0
1-vessel disease (70%) 53.3
2-vessel disease (70%) 26.3
3-vessel disease (70%) 18.8
Intervention in 1 vessel 88.9
Intervention in 2 vessels 10.5
Intervention in 3 vessels 0.6
Restenotic lesion 6.3
Thrombus 16.6
Visible calciﬁcation 20
Chronic total occlusion 2.2
Vascular closure device 32.3
Total contrast agent dose, ml (SD) 200 (89)
Values are % or % (SD). *Maximum advised contrast dose defined as [contrast dose5 ml kilogr
MACDmaximum advised contrast dose; MImyocardial infarction; other abbreviations as in
Figure 1. Proportion of Patients in the Cohort That Underwent Coronary
Intervention With an 8-F Guiding Catheter at a Given Hospital
The use of 8-F guide catheters, compared with 6-F guide catheters, rangeda
from 0.3% to 72.3% across various hospitals in the consortium.R: 1.68, 95% CI: 1.50 to 1.88, p  0.0001), and a greater
eed for blood transfusion (adjusted OR: 1.85, 95% CI: 1.62 to
.10, p  0.0001). Interestingly, even after adjusting for
omorbidities and propensity, the use of 8-F guide catheters
as associated with significantly greater post-procedural in-
ospital death (adjusted OR: 1.64, 95% CI: 1.25 to 2.14, p 
.0003) and in-hospital MACE (adjusted OR: 1.48, 95% CI:
.29 to 1.70, p  0.0001).
Not only was the observed mortality in the 7- and 8-F
uide catheter groups significantly higher than that of the
-F guide catheter group, the standardized mortality in the
-F group was also significantly higher (Fig. 3). Institutions
ere also ranked according to the 8-F guide use and divided
nto quartiles. Notably, mortality was significantly higher in
he 8-F guide catheter group in all quartiles, regardless of
he overall use of 8-F guides (Fig. 4).
In a propensity-matched cohort, in which each patient
reated with a 6-F guide was matched to a similar patient
reated with an 8-F guide, the use of an 8-F guide was
ignificantly associated with PCI-associated vascular com-
lications, significant drop in Hgb, post-PCI transfusion,
ost-PCI MI, and in-hospital MACE, with a trend toward
ncreased CIN and in-hospital death (Table 5).
iscussion
n this study, when compared with PCI performed with 6-F
uide catheters, the use of 7- or 8-F guide catheters was
ng Catheter
7-F 8-F
p Value(n  32,676) (n  6,059)
17.5 14.7 0.0001
32.5 29.7 0.0001
19.4 16.5 0.0001
2.4 4.2 0.0001
9.7 14.7 0.0001
48.2 48.1 0.0001
28.5 27.7 0.0001
22.0 23.5 0.0001
85.2 85.6 0.0001
13.0 13.0 0.0001
1.4 1.4 0.0001
8.3 6.3 0.0001
15.3 15.9 0.0001
20.7 32.7 0.0001
2.5 3.4 0.0001
14.4 11.1 0.0001
223 (96) 247 (119) 0.0001
y weight)/creatine (mg/ml)].
.Guidi
am (bodssociated with unadjusted use of larger volume of contrast
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640gent, greater likelihood of post-procedure nephropathy,
ore vascular complications, greater post-procedure drop in
gb, greater need for post-procedure blood transfusion,
igher mortality, and more frequent post-procedural
ACE. These findings were confirmed after adjustment
or confounding patient and procedural variables for both 7-
nd 8-F guides compared with 6-F guide catheters, specif-
cally related to post-procedure nephropathy, vascular com-
lications, greater drop in Hgb, and need for post-PCI
ransfusion. The use of 8-F guides was also associated with
Table 3. Unadjusted Outcomes for Patients With 6-, 7-, and 8-F Guide Cath
In-Hospital Outcomes
Aggregate
(n  103,070) (n 
CIN† 3.83
NRD 0.24
Vascular complication 2.50
Vascular complication with VCD 2.37
Vascular complication without VCD 2.62
Gastrointestinal bleeding 1.19
Drop in hemoglobin 3 (g/dl)‡ 9.20
Post-procedure transfusion 5.15
Emergency CABG 0.39
Any CABG§ 1.08
Revascularization (same site) 0.59
MI 1.66
Stroke 0.37
Death 1.13
MACE 4.29
Values are %. *The p value for comparison of 6-, 7-, and 8-F categories. †[Peak creatinine –basel
hemoglobin]3 g/dl. §Any CABG includes emergency and nonemergency CABG. Major adverse c
CIN contrast-induced nephropathy; MACEmajor adverse cardiac event; NRD nephropath
Table 4. Unadjusted and Adjusted Odds Ratios for Adverse Events for 6-, 7
Unadjusted OR for 7-F and 8-F
7-F vs. 6-F
In-Hospital Outcomes OR p Value OR
CIN* 1.30 0.0001 1.88
NRD 1.01 0.95 2.27
Vascular complications 1.15 0.001 1.66
Gastrointestinal bleeding 1.14 0.04 1.74
Drop in hemoglobin 3 g/dl† 1.22 0.0001 1.74
Post-procedure transfusion 1.21 0.0002 2.05
Emergency CABG 0.96 0.72 2.21
Any CABG‡ 1.09 0.20 1.90
MI 1.12 0.04 1.73
Stroke 1.27 0.03 1.89
Death 1.24 0.0008 2.50
MACE§ 1.19 0.0001 1.95
*[Peak creatinine –baseline creatinine]0.5 (mg/dl). Patients with a history of renal failurewith dialy
nonemergency CABG. §Composite of stroke, MI, death, any CABG, and repeat PCI (same site).OR odds ratio; other abbreviations as in Tables 1 and 3.reater adjusted incidence of post-PCI nephropathy requir-
ng dialysis, myocardial infarction, CABG, death and
ACE. Importantly, these findings are from a multicenter
egistry and include data gathered prospectively from pro-
edures performed by more than 100 interventionalists and,
herefore, represent a large cross-section of contemporary
nterventional cardiology practice.
Whereas the higher adjusted in-hospital post-PCI
ACE and mortality were associated with 8-F guide
atheter size, a larger percentage of patients underwent
ize
35)
7-F
(n 32,676)
8-F
(n  6,059) p Value*
4.38 6.21 0.0001
0.22 0.51 0.0001
2.69 3.85 0.0001
2.06 3.6 0.04
2.79 3.89 0.0001
1.27 1.93 0.0001
10.23 14.01 0.0001
5.26 9.23 0.0001
0.35 0.81 0.0001
1.08 1.86 0.0001
0.67 0.53 0.0007
1.74 2.67 0.0001
0.42 0.63 0.0005
1.20 2.38 0.0001
4.54 7.21 0.0001
tinine] 0.5 (mg/dl). Patients with a history of dialysis excluded. ‡[Baseline hemoglobin – nadir
events are a composite of stroke, MI, post-PCI CABG or repeat PCI (same site), or death.
ing dialysis; VCD vascular closure device; other abbreviations as in Tables 1 and 2.
-F Guide Catheter Utilized
F Adjusted OR for 7-F and 8-F vs. 6-F
. 6-F 7-F vs. 6-F 8-F vs. 6-F
p Value OR p Value OR p Value
0.0001 1.18 0.0004 1.44 0.0001
0.0001 0.88 0.40 1.63 0.03
0.0001 1.19 0.0002 1.68 0.0001
0.0001 1.14 0.05 1.46 0.0007
0.0001 1.12 0.0001 1.72 0.0001
0.0001 1.08 0.03 1.80 0.0001
0.0001 0.79 0.06 1.55 0.01
0.0001 0.91 0.23 1.51 0.0005
0.0001 1.00 0.95 1.39 0.0004
0.0002 1.18 0.15 1.22 0.34
0.0001 1.11 0.22 1.34 0.03
0.0001 1.06 0.13 1.37 0.0001
xcluded. †Baseline hemoglobin – nadir hemoglobin3 g/dl.‡Any CABG includes emergency andeter S
6-F
64,3
3.39
0.22
2.35
2.41
2.33
1.12
8.55
4.72
0.37
0.99
0.48
1.56
0.33
0.97
3.84
ine crea
ardiac-, or 8
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8-F vs
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641ultivessel PCI in the 8-F group. Multivessel PCI has been
ssociated with increased periprocedural MI, but no differ-
nces in long-term mortality (21). Post-PCI complications,
Figure 2. Adjusted and Unadjusted In-Hospital Outcomes of Patients Treat
The ﬁrst plot (left) shows unadjusted odds ratios; the second plot (center) sho
propensity-adjusted odds ratios. Contrast-induced nephropathy, drop in hemo
death, and major adverse cardiac events were more common in patients treat
the propensity to receive an 8-F guide catheter. Nephropathy requiring dialysi
patients, but these differences were not signiﬁcant after risk adjustment or aft
nary artery bypass graft; CIN  contrast-induced nephropathy; Drop in Hgb 
 major adverse cardiac event; MI  myocardial infarction; NRD  nephropat
vascular complication.
Figure 3. Standardized Mortality Rate in Patients Undergoing PCI Based U
The observed and predicted mortality of 8-F guide catheter PCI patients was h
both). The observed mortality in patients treated with 8-F guide catheters was
those who underwent PCI with a 6-F guide was lower than the predicted mor
patients treated with an 8-F guide was signiﬁcantly higher than the SMR of pa
ous coronary intervention; SMR  standardized mortality rate.owever, such as CIN (20,22) and transfusion (23) have
een independently associated with adverse outcome, in-
luding increased MACE and mortality. Hence, it is plau-
th 8-F Guiding Catheters Versus 6-F Guiding Catheters
k-adjusted odds ratios; and the third plot (right) shows risk-adjusted and
by 3 g/dl, transfusion, coronary artery bypass graft, myocardial infarction,
h the 8-F guide catheter, even after risk adjustment or after adjustment for
rointestinal bleeding, and stroke were more common in the 8-F treated
stment for the propensity to receive an 8-F guide catheter. CABG  coro-
in hemoglobin by 3 g/dl; GI  gastrointestinal; Hgb  hemoglobin; MACE
uiring dialysis; Post Proc Trans  post-procedure transfusion; Vasc Comp 
e Guide Catheter Size
than the observed mortality of the 6- and 7-F guide patients (p  0.05 for
r than the predicted mortality (p  0.05) and the observed mortality of
p  0.05). The SMR (a ratio of observed mortality and predicted mortality) of
who underwent PCI with a 6- or 7-F catheter (p  0.05). PCI  percutane-ed Wi
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642ible that a procedural variable, such as PCI guide catheter
ize, may have direct impact on the occurrence of severe,
dverse outcomes, mediated by the increased occurrence of
ore moderate renal, vascular, and cardiac complications.
urthermore, the consistency of the mortality data across
he consortium, regardless of baseline institutional 8-F
uide use, the standardized mortality rate, and propensity
djustment all suggest that larger guide catheter use is
ssociated with increased mortality.
This study represents the largest investigation that relates
arger guide catheter size directly to contrast agent use and
omplications associated with PCI. Previous investigators
Figure 4. Hospital Quartiles According to Guide Use and Mortality
Participating hospitals were ranked according to 8-F guide use and divided
into quartiles. Within each quartile, the mortality of patients who under-
went PCI with 8-F guides was signiﬁcantly greater than that of the 6-F
guide groups (p  0.003). Q  quartile; other abbreviations as in Figure 3.
Table 5. In-Hospital Outcomes of the Propensity Match
In-Hospital Outcomes
6-F Gu
(n  4,0
CIN* 148 (4.8
NRD 14 (0.3
Vascular complication 119 (2.9
Gastrointestinal bleeding 71 (1.7
Decrease hemoglobin 3 g/dl† 355 (8.8
Transfusion 277 (6.9
Emergency CABG 29 (0.7
Any CABG‡ 62 (1.5
Repeat revascularization 24 (0.6
MI 80 (2.0
Stroke 22 (0.5
Death 64 (1.6
MACE§ 224 (5.5
*[Peak creatinine –baseline creatinine]0.5 (mg/dl). Patientswith a hi
hemoglobin]3 g/dl. ‡Any CABG includes emergency and nonemerg
site).Abbreviations as in Tables 1 and 3.24,25) have related catheter size directly to volume of
ontrast medium used during diagnostic angiography, but
id not evaluate outcome variables. Using measurement of
njection pressure, volume, and time, Dodge et al. (25)
etermined that as catheter sizes increase, injection volume
nd rate increased as injection duration decreased. Vascular
omplications associated with PCI can increase morbidity,
rolong hospital stay, and increase costs (26–28). In addi-
ion, vascular access site bleeding complications can increase
he need for transfusion (26,29). The association between
heath size and vascular access site complications, however,
s controversial. In a study of 2,400 PCIs from 1991,
CI-related vascular access site complications were associ-
ted with 8-F or larger guide catheters (30). Conversely, a
tudy of the predictors of retroperitoneal hematoma associ-
ted with PCI in 3,508 consecutive patients found no
ssociation of retroperitoneal hematoma with sheath size
31). One single center trial randomized 414 patients to
CI with 6- or 7-F guide catheters. Although there was
ore contrast medium used in the 7-F guide patients, there
as no difference in vascular complications between the
roups (32). In a study designed to identify predictors of
ascular access site complications associated with PCI, the
orthern New England Cardiovascular Disease Study
roup evaluated 18,137 PCI procedures. Unfortunately,
heath size was not collected in the database and, therefore,
ot included in the analysis (33).
Advancement in technology has facilitated the use of
maller guide catheters to perform PCI. In fact, our data
uggest a trend over the last 6 years to use smaller guides
ithin the consortium (Fig. 5). However, as seen in this
tudy, there are a significant number of interventionalists
hort Categorized by 6- Versus 8-F Guide Catheter Size
8-F Guide
(n  4,008) p Value
180 (5.91%) 0.08
23 (0.57%) 0.1
167 (4.17%) 0.004
81 (2.02%) 0.4
504 (12.57%) 0.0001
392 (9.78%) 0.0001
34 (0.85%) 0.5
79 (1.97%) 0.15
25 (0.62%) 0.9
121 (3.02%) 0.003
24 (0.60%) 0.8
87 (2.17%) 0.06
303 (7.56%) 0.0003
renal failurewith dialysis are excluded.†[Baseline hemoglobin – nadir
BG. §Composite of stroke, MI, death, any CABG, and repeat PCI (sameed Co
ide
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643ho prefer larger guide catheters for PCI. Moreover, some
nterventional textbooks recommend the use of larger guide
atheters (34). The device industry has focused on the
evelopment of technologies compatible with smaller guide
atheters largely due to the perception that the interven-
ional cardiology community prefers smaller catheters, be-
ause they were linked with fewer vascular complications
nd shorter post-procedure recovery. The data from this
tudy suggest that the use of smaller guiding catheters
uring PCI is associated with significantly better outcome,
ncluding improved post-procedural morbidity and reduced
ortality.
tudy limitations. The results of this study are based upon
bservational data, and outcomes were not centrally
djudicated. As such, the choice of guide catheter size
as not randomized, but determined at the discretion of
he interventionalist at the time of the PCI. The use of
-F guiding catheters was associated with several clinical
actors that are correlated with adverse PCI outcome,
ncluding significantly more patients with baseline cardi-
genic shock, more multivessel disease, and more mul-
ivessel PCI. These and multiple other clinical factors
ere included in the risk adjustment, propensity, and
tandardized mortality analyses. However, data related
pecifically to intervention on bifurcation lesions was not
ollected during the majority of the time frame included
n this registry and thus not included in the analyses. In
ddition, it is possible that we were unable to adjust for
ther unknown factors that may influence guide of choice
nd procedural outcomes. Finally, the vast majority of
CIs in this registry were performed with femoral arterial
ccess. Though the bulk of PCIs performed via brachial
r radial artery access are completed with smaller guide
Figure 5. Temporal Use of 6-, 7-, and 8-F Guide Catheters for PCI
There was a signiﬁcant decline in the use of 8-F guide catheters for PCI over t
Figure 3.atheters, the influence of brachial or radial artery accessn PCI outcome could not be directly assessed in this
egistry.
onclusions
ompared with smaller 6-F guide catheters, PCIs per-
ormed with larger 7- and 8-F guide catheters are associated
ith more contrast agent use, more CIN, more significant
ost-PCI Hgb drop, and a greater need for blood transfu-
ion. In addition, 8-F guides were associated with increased
ephropathy requiring dialysis, in-hospital MACE, and an
ncreased mortality. These data suggest that selection of
maller guide catheters may result in improved clinical
utcomes in patients undergoing contemporary PCI.
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